|
|
Article: NORD Honors Celgene Corporation for Development of THALOMID(R) (thalidomide).
- Article from:
- PR Newswire
- Article date:
- May 10, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WASHINGTON, May 10 /PRNewswire/ -- The National Organization for Rare Disorders, Inc.(R) (NORD) will honor Celgene Corporation for its development of the orphan drug THALOMID(R) (thalidomide) to treat leprosy at its 16th Annual Tribute Banquet on Monday evening, May 10th at the Capital Hilton Hotel in Washington, D.C.
"The gala celebrates the strong partnership between the patient community, medical researchers, health-related industries, and the federal government to promote development of new treatments for rare diseases," said NORD President Abbey S. Meyers.
Celgene's first product, THALOMID(R) (thalidomide), was approved by the U.S. Food and Drug ...